Direct emissions
51,517
tCO2e
V
Valeant Pharmaceuticals International, Inc.
Explore carbon emissions data for Valeant Pharmaceuticals International, Inc.. Mycelium helps you review reported emissions, disclosure status, Scope 1, Scope 2 and Scope 3 data, climate targets and sustainability information in one company profile.
This profile brings together available carbon emissions data for Valeant Pharmaceuticals International, Inc., including reported figures, modelled estimates, disclosure documents and sustainability indicators, so you can review its emissions and compare its performance against similar companies. Read how we source and check this data.
Emissions
Carbon emissions
Total yearly emissions across all scopes
1,237,169 tCO2e (Market Based)
Scope 1
tCO2e
51,517
Scope 2 (Market Based)
tCO2e
67,484
Scope 3 total
tCO2e
1,118,168
Scope 3 reported
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
Provenance
Emissions
Factors
162,058
kgCO2e / £M
Supplier specific emission factors (kgCO2e / £M)
Modelled
Reported
Scope 1 + 2
Direct + purchased energy
15,588
15,588
Upstream
+ upstream Scope 3
62,398
15,588
Total
+ all Scope 3
162,058
15,588
Which figure should I use?
Use Modelled. It is the most complete view: any categories the company hasn't disclosed are filled with industry-typical estimates, so a transparent company isn't unfairly penalised against one that simply hasn't reported.
Reported counts only emissions the company has filed itself. A blank or low Reported cell doesn't mean those emissions don't exist, just that the company hasn't disclosed them.
When Reported sits close to Modelled, that is a positive signal. The company has disclosed most of its salient emissions and there's little gap for the model to fill. Even then, Modelled is the right figure to use for a like-for-like comparison across companies.
Sustainability
Snapshot
Based on reported data, retrieved with AI
- Valeant Pharmaceuticals International, Inc. reported 1,237,169 tCO₂e in 2024.
- Scope 3 accounted for 90% of emissions.
- Scope 2 reported under the market based methodology.
According to available emissions disclosures, Valeant Pharmaceuticals International, Inc. reported total yearly emissions of 1,237,169 tCO₂e in 2024. Scope 3 emissions accounted for 90% of reported output, indicating supply chain activity, purchased goods and services, business travel, and wider operational dependencies were the most significant contributors to the company's carbon footprint.
The company achieved a Mycelium Score of 0.2, placing it well below average for its sector for sustainability performance, and received a transparency score of 3.0, pointing to very little public detail on their key emissions.
Total Emissions across all scopes
1,237,169 tCO2e (Market Based)
Scope 1 emissions
Direct emissions from sources the company owns or controls, such as fuel use, facilities and vehicles.
Scope 2 emissions
Indirect emissions from purchased energy, including electricity, heating and cooling.
Location based
57,128
tCO2eMarket based
67,484
tCO2eScope 3 emissions
Wider value chain emissions across the 15 GHG Protocol categories, from purchased goods and business travel to investments, where reported.
Cat 1
Purchased goods & services
276,660
tCO2eCat 2
Capital goods
11,528
tCO2eCat 3
Fuel & energy related activities
11,528
tCO2eCat 4
Upstream transportation & distribution
11,528
tCO2eCat 5
Waste generated in operations
11,528
tCO2eCat 6
Business travel
11,528
tCO2eCat 7
Employee commuting
11,528
tCO2eCat 8
Upstream leased assets
11,528
tCO2eCat 9
Downstream transportation & distribution
11,528
tCO2eCat 10
Processing of sold products
11,528
tCO2eCat 11
Use of sold products
691,650
tCO2eCat 12
End-of-life treatment of sold products
11,528
tCO2eCat 13
Downstream leased assets
11,528
tCO2eCat 14
Franchises
11,528
tCO2eCat 15
Investments
11,528
tCO2e15 values were derived via Mycelium's normalisation process rather than reported by the company. Cells marked “–” were not disclosed.
Contact Info
Browse carbon emissions data by industry
Jump straight into the sectors users explore most, or view all industries.
How scoring works
How the Mycelium Score is calculated
The Mycelium Score is out of 10. Up to 6.5 points reflect carbon intensity vs sector peers (emissions normalised against revenue). The remaining 3.5 reflect data quality: third-party verified, profile claimed by the company, and full disclosure across all reporting categories.
A higher score means lower carbon intensity than sector peers, backed by data that's third-party verified, claimed by the company, and fully disclosed. Valeant Pharmaceuticals International, Inc.'s score sits at the top of this page and in the score panel.
How the Transparency Score is calculated
The Transparency Score measures how much of a company's key emissions data is publicly disclosed, graded from A (very high) down to F (very low). Crucially, it weights each gap by how material that bucket is for the company's industry, so an undisclosed category where the bulk of emissions sit hurts far more than a minor one.
For Valeant Pharmaceuticals International, Inc., the single biggest gap is Use of sold products (Scope 3 Category 11). Mycelium estimates it accounts for around 56% of the company's total footprint, typically the largest source of emissions for a Health Care company, yet it hasn't been disclosed. Leaving a bucket this large unreported is what's holding the transparency score down.
Other material categories Valeant Pharmaceuticals International, Inc. hasn't disclosed:
- Purchased goods & services (Scope 3 Category 1), around 22% of the estimated footprint
In total, roughly 78% of Valeant Pharmaceuticals International, Inc.'s estimated emissions sit in categories it hasn't reported. Disclosing these would be the fastest way to raise the transparency score.
Read the full scoring methodology
Our white paper covers exactly how the Mycelium Score and Transparency Score are calculated, including the normalisation process and what earns a 10/10.
Download the white paper (PDF)
Valeant Pharmaceuticals International, Inc. carbon emissions FAQs
What are Valeant Pharmaceuticals International, Inc.'s carbon emissions?
In its 2024 reporting year, Valeant Pharmaceuticals International, Inc. disclosed total emissions of 1,237,169 tCO2e across all scopes. Scope 3 accounted for the largest share, around 90% of the total.
Does Valeant Pharmaceuticals International, Inc. report Scope 1, Scope 2 and Scope 3 emissions?
For 2024, Valeant Pharmaceuticals International, Inc.'s available disclosure covers Scope 1 (51,517 tCO2e), Scope 2 (67,484 tCO2e). Figures not reported by the company are shown as modelled estimates and labelled as such.
How transparent is Valeant Pharmaceuticals International, Inc.'s emissions reporting?
Valeant Pharmaceuticals International, Inc. has a Mycelium transparency score of 3 out of 100. The score weights each emissions category by how material it is for the company's industry, so it reflects whether the disclosures that matter most have been made.
Is Valeant Pharmaceuticals International, Inc. sustainable?
Mycelium measures sustainability through carbon emissions data rather than giving a yes or no verdict. Valeant Pharmaceuticals International, Inc. has a Mycelium Score of 0.2 out of 10, which reflects its emissions intensity against sector peers together with how transparent and well-verified its reporting is. The emissions figures, disclosure documents and climate targets on this page give the fuller picture.
Is Valeant Pharmaceuticals International, Inc. environmentally friendly?
Carbon emissions are one measurable part of environmental impact, and the part Mycelium tracks. Valeant Pharmaceuticals International, Inc. disclosed 1,237,169 tCO2e for 2024, and its Mycelium Score of 0.2 out of 10 shows how that performance compares with similar companies in its sector.
Learn more about our methodology and where this data comes from.
